As the first and only drug demonstrating clinical benefits in a phase III study, tebentafusp (also called IMCgp100) is an advanced ImmTAC molecule targeting HLA-A*02:01-restricted peptide gp100, which can kill targeted tumor cells by immune synapse [35,134]. The gene discussed is PMEL; the disease is neoplasm.